Advanced Biomed Inc - Multiplikator forward rega marang pendapatan ADVB
Advanced Biomed Inc (ADVB) is protected by biomarker patents and strict regulatory oversight, as confirmed by the forward P/S trajectory on the GURU.Markets chart, where the metric is fixed at 0.00. The business relies on the scalable sale of disposable cartridges alongside stable equipment costs. Additionally, the company is implementing software robots to accelerate the processing of diagnostic data arrays.
Ringkesan rincian data analitis advanbiomed.com (ADVB)
- rega saiki lan proyeksi nilai saham:
- rincian nilai pasar emiten:
- rincian valuasi buku bisnis:
- rincian struktur utang lan likuiditas bisnis:
Total Utang marang Modal Advanced Biomed Inc|ADVB - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Advanced Biomed|ADVB - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku ADVB|ADVB - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Advanced Biomed|Rasio cepet advanbiomed.com
- rincian asil keuangan lan kelipatan valuasi:
ADVB - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Advanced Biomed Inc|ADVB - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Advanced Biomed|ADVB - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ADVB|ADVB - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Advanced Biomed|ADVB - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan advanbiomed.com|ADVB - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Advanced Biomed Inc
- data total pendapatan lan volume dodolan:
Analisis wiwitan perusahaan:Advanced Biomed Corp ADVB
Cancer diagnostic automation via Advanced Biomed Inc (ADVB) microfluidic platforms determines the potential for revenue scaling, which is reflected in the company's forward P/S valuation. This indicator correlates current market capitalization with projected sales volume, allowing investors to differentiate fundamental undervaluation of a mature business from a systemic slowdown in expansion and the risk of invested capital stagnation.
Analisis pesaing Advanced Biomed Inc
Multiplikator Forward P/S ONC (BeiGene)|HALO: Kapitalisasi marang prakiraan pendapatan|RVMD: Multiplikator forward rega marang pendapatan|AAPG: Rasio rega marang prakiraan pendapatan|CGON: Multiplikator Forward P/S|urogen.com (URGN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|Kapitalisasi marang prakiraan pendapatan PSNL (Personalis Inc)|Multiplikator Forward P/S ERAS|Multiplikator forward rega marang pendapatan Delcath Corp DCTH|Multiplikator Forward P/S YMAB (Y-mAbs Therapeutics)|aurabiosciences.com (AURA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Candel - Multiplikator Forward P/S|ARAY (Accuray Inc) - Kapitalisasi marang prakiraan pendapatan|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|Actuate Therapeutics Inc - Rega forward marang dodolan|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan HURA|Multiplikator Forward P/S TARA|Rasio kapitalisasi marang dodolan sing dikarepake Fate Therapeutics Inc|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|TScan Therapeutics Inc (TCRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CSBR - Rasio rega marang prakiraan pendapatan|XBiotech Inc. (XBIT) - Multiplikator forward rega marang pendapatan|CVM: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OS Therapies Inc. (OSTX)|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ARTV (Artiva)|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Ltd.)|VERU (verupharma.com) - Rega forward marang dodolan|Multiplikator Forward P/S TPST (Tempest Therapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Xilio Therapeutics Inc (XLO)|RENB - Rasio rega marang prakiraan pendapatan|MURA (Mural Oncology plc) - Kapitalisasi marang prakiraan pendapatan|KAPA: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Multiplikator Forward P/S Curis Corp|Multiplikator Forward P/S APLM|Tharimmune Corporation - Kapitalisasi marang prakiraan pendapatan|Genprex, Inc. - Multiplikator forward rega marang pendapatan|Calidi Biotherapeutics Inc. - Rasio rega marang prakiraan pendapatan|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|XBIO: Rasio rega marang prakiraan pendapatan|SLRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Kitov Pharma|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S beigene.com|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Viracta Therapeutics|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Inc - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan AAPGV
